GlassScriptPhysician profile
Kim Stopczynski
NPI 1538581558
$12,799.60
in general payments reported to CMS, 2019-2025
68 companies · $4,376 in 2025
The $4,376 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $303 · 2022: $1,828 · 2023: $2,393 · 2024: $3,899 · 2025: $4,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,787 · Long Term Medical Supply Or Device Loan: $881.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,787.25 |
| Long Term Medical Supply Or Device Loan | $880.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,334.85 | 2022-2025 | |
| Pfizer INC. | $798.17 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $649.26 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $564.71 | 2021-2025 | Darzalex, Tecvayli, Rybrevant |
| Astrazeneca Pharmaceuticals LP | $539.55 | 2021-2025 | Enhertu, Imfinzi, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $531.57 | 2021-2025 | Opdivo, Opdualag |
| Lilly USA, LLC | $513.28 | 2021-2025 | Verzenio, Jaypirca, Retevmo |
| Gilead Sciences, INC. | $473.46 | 2022-2025 | Trodelvy |
| Abbvie INC. | $442.68 | 2021-2025 | |
| Daiichi Sankyo INC. | $418.99 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $404.69 | 2023-2025 | Jakafi, Monjuvi, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $331.40 | 2022-2025 | Fruzaqla, Alunbrig, Iclusig |
| Eisai INC. | $295.81 | 2022-2025 | |
| Celgene Corporation | $273.37 | 2022-2025 | Reblozyl, Pomalyst |
| Bayer Healthcare Pharmaceuticals INC. | $255.30 | 2021-2025 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $230.59 | 2022-2025 | Zoladex |
| Seagen INC. | $223.02 | 2022-2023 | Tukysa, Tivdak, Adcetris |
| Jazz Pharmaceuticals INC. | $219.86 | 2022-2025 | |
| Beone Medicines USA, INC. | $216.53 | 2025 | Tevimbra |
| Genzyme Corporation | $177.08 | 2022-2025 | |
| Glaxosmithkline, LLC. | $153.63 | 2023-2025 | Ojjaara, Jemperli, Zejula |
| Amgen INC. | $149.07 | 2021-2023 | Kyprolis, Blincyto |
| Astellas Pharma US INC | $146.92 | 2023-2025 | Xospata, Vyloy |
| Penumbra, INC. | $140.89 | 2025 | Indigo System |
| Regeneron Healthcare Solutions, INC. | $125.36 | 2021-2025 | Libtayo, Lynozyfic |
| Pharmacyclics LLC, An Abbvie Company | $119.76 | 2022-2023 | Imbruvica, Epkinly |
| Geron Corporation | $115.42 | 2025 | Rytelo |
| Array Biopharma INC | $103.16 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Sobi, INC | $99.63 | 2022-2025 | |
| Beigene USA, INC. | $97.43 | 2024-2025 | Tevimbra |
| Aveo Pharmaceuticals, INC. | $97.37 | 2023-2025 | Fotivda |
| Puma Biotechnology, INC. | $95.82 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $95.00 | 2022 | |
| Emd Serono, INC. | $91.55 | 2022-2025 | |
| Genentech USA, INC. | $90.39 | 2024-2025 | Polivy, Tecentriq, Alecensa |
| Legend Biotech USA INC. | $90.25 | 2024-2025 | Carvykti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.67 | 2022-2024 | Gilotrif |
| Kyowa Kirin, INC. | $72.72 | 2023-2025 | Poteligeo |
| Myriad Genetic Laboratories, INC. | $64.92 | 2022-2025 | Myrisk |
| Agios Pharmaceuticals, INC. | $59.00 | 2023-2025 | Pyrukynd |
| Syndax Pharmaceuticals, INC. | $56.26 | 2025 | |
| Kite Pharma, INC. | $55.38 | 2021-2023 | Yescarta |
| Stemline Therapeutics INC. | $55.36 | 2025 | Orserdu |
| Cti Biopharma Corp. | $48.43 | 2022-2023 | Vonjo |
| Servier Pharmaceuticals LLC | $45.42 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $41.06 | 2024-2025 | Monoferric |
| G1 Therapeutics, INC. | $37.92 | 2023 | Cosela |
| Ipsen Biopharmaceuticals, INC | $37.05 | 2022-2024 | Somatuline Depot, Onivyde |
| Ge Healthcare | $36.37 | 2022 | |
| Epizyme, INC. | $35.30 | 2022 | |
| Rigel Pharmaceuticals, INC. | $34.33 | 2024 | Tavalisse, Rezlidhia |
| Springworks Therapeutics, INC. | $27.74 | 2024 | Ogsiveo |
| Dendreon Pharmaceuticals LLC | $25.23 | 2024 | Provenge |
| Immunocore Limited | $25.08 | 2025 | Kimmtrak |
| Telix Pharmaceuticals | $24.57 | 2023 | Illuccix |
| Mirati Therapeutics, INC. | $21.19 | 2024 | Krazati |
| Exelixis INC. | $20.85 | 2024 | Cabometyx |
| Csl Behring | $20.29 | 2022 | |
| Accord Healthcare, INC. | $19.75 | 2023 | |
| Alexion Pharmaceuticals, INC. | $19.22 | 2025 | Ultomiris |
| Karyopharm Therapeutics INC. | $18.04 | 2024 | Xpovio |
| Deciphera Pharmaceuticals INC. | $17.43 | 2023 | Qinlock |
| Blueprint Medicines Corporation | $16.59 | 2023 | Ayvakit |
| Sumitomo Pharma America, INC. | $16.46 | 2023 | Orgovyx |
| Alnylam Pharmaceuticals INC. | $15.63 | 2023 | Givlaari |
| Recordati_rare_diseases_inc. | $15.49 | 2023 | Sylvant |
| Novocure INC. | $14.53 | 2025 | Optune Lua (Novottf-200t) |
| Taiho Oncology, INC. | $14.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Stopczynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.